Lilly, Yabao collaborate on diabetes

Share this article:

Indiana's Eli Lilly has paired up with Beijing's Yabao Pharmaceutical to develop Lilly's experimental glucokinase activator LY2608204. The partners describe the pipeline treatment in a statement as a possible new way to address diabetes. The idea is that the activator would promote insulin secretion and lower the liver's glucose production, a combination the drug partners say “may exert powerful anti-hyperglycemic effects.”

The deal gives Yabao development and commercialization rights in China, while Lilly holds onto rights in all other geographies.

Data from the International Diabetes Foundation, which is comprised of diabetes associations in 170 countries and territories, indicates that China has the largest number of diabetics, with 98.4 million as of 2013. The IDF ranks the United States third, with 24.4 million, behind India, which counted 65.1 million last year.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions